Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Clinical Trial Study to Evaluate Efficacy and Safety of Anti COVID 19 Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients

NCT04891172 is registered in ClinicalTrials.gov with Dow University of Health Sciences as lead sponsor.

NCT NCT04891172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04891172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Clinical Trial Study to Evaluate Efficacy and Safety of Anti COVID 19 Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients
Lead sponsor
Dow University of Health Sciences
Phase
Phase 2/3
Overall status
Unknown status
Start date
August 1, 2021
Completion date
December 2, 2022
Enrollment
310 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19